Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Ongoing and future efforts in functional genomics in Alzheimer’s disease

Ornit Chiba-Falek, PhD, Duke University School of Medicine, Durham, NC, describes some of the ongoing efforts in functional genomics in Alzheimer’s disease (AD). For example, her lab is currently profiling the epigenome and transcriptome of subpopulations of neurons within the human brain in order to better understand the mechanisms that underlie AD on a single-cell level. For the future of functional genomics in AD, Dr Chiba-Falek stresses the importance of precision medicine, in particular the study of sex differences in the pathogenic impact of AD variants. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Prof. Chiba-Falek reports the following disclosures:
-Co-Founder at CLAIRIgene
-CLAIRIgene is negotiating the licensing of the technology developed in this study